uniQure N.V. (NASDAQ:QURE) ranks among the most oversold biotech stocks to invest in. William Blair reaffirmed its Market Perform rating for uniQure N.V. (NASDAQ:QURE) on November 11 while the company anticipates comments from regulators regarding its AMT-130 therapy. William Blair suggests that lobbyists and the medical community might put pressure on regulators to negotiate a quick route to BLA submission, citing the strong clinical results released last month and the early interest from patients and phy ...